Smith & Nephew plc (LON:SN - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,056.25 ($13.64) and traded as high as GBX 1,103.50 ($14.25). Smith & Nephew shares last traded at GBX 1,088.50 ($14.06), with a volume of 1,242,435 shares trading hands.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,180 ($15.24) price objective on shares of Smith & Nephew in a research note on Tuesday, January 14th.
View Our Latest Report on SN
Smith & Nephew Stock Performance
The firm's 50-day moving average price is GBX 1,061.24 and its 200-day moving average price is GBX 1,054.15. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The stock has a market cap of £11.89 billion, a P/E ratio of 39.06, a PEG ratio of 0.46 and a beta of 0.62.
Smith & Nephew Increases Dividend
The company also recently declared a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be paid a dividend of $0.23 per share. The ex-dividend date is Thursday, March 27th. This is a positive change from Smith & Nephew's previous dividend of $0.14. This represents a yield of 1.61%. Smith & Nephew's dividend payout ratio is presently 104.41%.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
